---
title: "Cytomx Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.418 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295142111.md"
datetime: "2026-08-06T20:46:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295142111.md)
  - [en](https://longbridge.com/en/news/295142111.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295142111.md)
generator: "portal-rs"
---

# Cytomx Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.418 M

Revenue: As of FY2026 Q2, the actual value is USD 1.418 M, missing the estimate of USD 12.34 M.

EPS: As of FY2026 Q2, the actual value is USD -0.09, missing the estimate of USD -0.0812.

EBIT: As of FY2026 Q2, the actual value is USD -20.61 M.

The provided reference indicates that the actual financial results, operational metrics, and any outlook or guidance for CytomX Therapeutics, Inc. are contained within an Exhibit 99.1 press release, titled “CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update”. However, the content of this exhibit is not provided within the given reference text. Therefore, no specific financial or operational metrics, nor any outlook or guidance, can be extracted from the provided text.

### Related Stocks

- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)

## Related News & Research

- [CytomX Therapeutics to present at Wells Fargo Annual Healthcare Conference fireside chat](https://longbridge.com/en/news/297649740.md)
- [CytomX says FDA grants Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer](https://longbridge.com/en/news/297182104.md)
- [What smart people are saying about Trump's acquisition of Venezuelan oil](https://longbridge.com/en/news/297464534.md)
- [CytomX Therapeutics doubles authorized common shares to 600 million](https://longbridge.com/en/news/290478262.md)
- [ZAWYA: BENEFIT's transaction value for H1 surges 6.1% to $51.2bln](https://longbridge.com/en/news/297725717.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**